Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.

Digestive diseases and sciences - 1 Jun 2006

Lee Jae-Lyun, Kim Jin Young, Ryu Min-Hee, Kang Hye Jin, Chang Heung Moon, Kim Tae-Won, Lee Hyoungnam, Park Ji Hyun, Kim Hee Cheol, Kim Jung Sun, Kang Yoon-Koo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abdominal Pain
Share to Benzamides
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Neurofibromatosis 1

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 16865565
DOI: 10.1007/s10620-006-8003-1

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.PMID 16865565Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

Positive response to imatinib in PDGFRB-related Kosaki overgrowth syndrome.Semantic proximity Read ↗

An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.Semantic proximity Read ↗

Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.Semantic proximity Read ↗

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.Semantic proximity Read ↗

A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.Semantic proximity Read ↗

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.Semantic proximity Read ↗

Gastrointestinal stromal tumors: who should get imatinib and for how long?Semantic proximity Read ↗

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.